Liminatus Pharma's stock surged 79.34% in after-hours trading following the announcement of a definitive merger agreement with InnocsAI LLC. The deal will bring a clinical-stage oncology portfolio to Liminatus, including a CAR-T therapy candidate authorized for early-stage trials in South Korea. The merger requires shareholder approval and SEC review, with a deadline of December 31. Despite the recent spike, Liminatus shares have dropped nearly 97% over the past year and trade near their 52-week low, indicating high risk for investors.
BTS Group AB reported a return to profitable growth in Q1 2026, with net sales of 602 million SEK, a 5% increase adjusted for currency effects, including 2% organic growth. EBITA rose 5% to 62 million SEK, improving the EBITA margin to 10.3% from 9.1...
Futurionex Blockchain Trading Ltd. has launched an update to its AI Quant 2.0 system, enhancing high-frequency trading execution to improve efficiency from strategy signals to order completion. This upgrade allows faster data capture and order execut...
Futurionex has enhanced its AI Quant 2.0 platform by integrating high-frequency execution capabilities, improving the speed and efficiency of converting trading strategy signals into actual trades. This upgrade addresses the critical need for rapid o...
Charter Communications is nearing the end of a large capital expenditure cycle, with CAPEX expected to drop from about $12 billion in 2026 to $8 billion, enabling free cash flow of $8-9 billion by 2027-2028. The company’s business model relies heavil...
Equinor ASA announced a cash dividend of USD 0.39 per share for the fourth quarter of 2025, which translates to NOK 3.6041 per share based on the average USD/NOK exchange rate. The dividend will be paid to shareholders on the Oslo Stock Exchange and ...
